Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The benefits and harms of antipsychotics are relatively well studied in adults. However,
there is a lack of scientifically valid studies regarding the benefits and harms of
antipsychotics in children and adolescents with psychosis.
The main objective of the TEA trial is to compare the efficacy and adverse reactions of two
antipsychotics (quetiapine versus aripiprazole) in children and adolescents between 12-17
years of age with psychotic symptoms on psychopathology, cognitive deficits, and daily
functioning. Furthermore, the trial will focus on adverse reaction profiles of the two
antipsychotics as well as early predictors of later sustained clinical effects of these
antipsychotics.
Phase:
Phase 4
Details
Lead Sponsor:
Anne Katrine Pagsberg
Collaborators:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University Allocated inheritance from Elizabeth Stevn and Niels Rindom, Denmark AP Moeller Foundation Capital Region Pharmacy, Denmark Copenhagen Trial Unit, Center for Clinical Intervention Research Psychiatric Centre Copenhagen, Denmark Research Institute for Biological Psychiatry, Sct. Hans Hospital, Denmark The Psychiatric Centre for Children and Adolescents in Bispebjerg, Denmark The Research Council for Health and Disease, Denmark Tryg Fonden, Denmark